Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

A qualitative study evaluating causality attribution for serious adverse events during early phase oncology clinical trials.

Mukherjee SD, Coombes ME, Levine M, Cosby J, Kowaleski B, Arnold A.

Invest New Drugs. 2011 Oct;29(5):1013-20. doi: 10.1007/s10637-010-9456-9. Epub 2010 May 29.

PMID:
20512397
2.

[The analysis of physicians' work: announcing the end of attempts at in vitro fertilization].

Santiago-Delefosse M, Cahen F, Coeffin-Driol C.

Encephale. 2003 Jul-Aug;29(4 Pt 1):293-305. French.

PMID:
14615699
3.

The NCI All Ireland Cancer Conference.

Johnston PG, Daly PA, Liu E.

Oncologist. 1999;4(4):275-277.

4.

Reporting of serious adverse events during cancer clinical trials to the institutional review board: an evaluation by the research on adverse drug events and reports (RADAR) project.

Belknap SM, Georgopoulos CH, Lagman J, Weitzman SA, Qualkenbush L, Yarnold PR, Edwards BJ, McKoy JM, Trifilio SM, West DP.

J Clin Pharmacol. 2013 Dec;53(12):1334-40. doi: 10.1002/jcph.177. Epub 2013 Sep 25.

PMID:
24030903
5.
6.
7.

The experiences of children enrolled in pediatric oncology research: implications for assent.

Unguru Y, Sill AM, Kamani N.

Pediatrics. 2010 Apr;125(4):e876-83. doi: 10.1542/peds.2008-3429. Epub 2010 Mar 29.

PMID:
20351001
8.

Views of American oncologists about the purposes of clinical trials.

Joffe S, Weeks JC.

J Natl Cancer Inst. 2002 Dec 18;94(24):1847-53.

PMID:
12488478
9.

[Diagnostic structured interviews in child and adolescent's psychiatry].

Renou S, Hergueta T, Flament M, Mouren-Simeoni MC, Lecrubier Y.

Encephale. 2004 Mar-Apr;30(2):122-34. Review. French.

PMID:
15107714
10.

Phase 0 clinical trials in oncology: a paradigm shift for early drug development?

Takimoto CH.

Cancer Chemother Pharmacol. 2009 Mar;63(4):703-9. doi: 10.1007/s00280-008-0789-4. Epub 2008 Jul 10. Review.

PMID:
18615251
11.

Quality of methods for assessing and reporting serious adverse events in clinical trials of cancer drugs.

Belknap SM, Georgopoulos CH, West DP, Yarnold PR, Kelly WN.

Clin Pharmacol Ther. 2010 Aug;88(2):231-6. doi: 10.1038/clpt.2010.79. Epub 2010 Jun 23.

PMID:
20571489
12.

Making the investigational oncology pipeline more efficient and effective: are we headed in the right direction?

LoRusso PM, Anderson AB, Boerner SA, Averbuch SD.

Clin Cancer Res. 2010 Dec 15;16(24):5956-62. doi: 10.1158/1078-0432.CCR-10-1279. Review.

13.

Nonsomatic treatment of depression.

Sherrill JT, Kovacs M.

Child Adolesc Psychiatr Clin N Am. 2002 Jul;11(3):579-93. Review.

PMID:
12222084
14.

Patients' decision-making process regarding participation in phase I oncology research.

Agrawal M, Grady C, Fairclough DL, Meropol NJ, Maynard K, Emanuel EJ.

J Clin Oncol. 2006 Sep 20;24(27):4479-84.

PMID:
16983117
15.
16.

American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.

American Society of Clinical Oncology.

J Clin Oncol. 2003 Jun 15;21(12):2397-406. Epub 2003 Apr 11.

PMID:
12692171
17.

User-centered research on breast cancer patient needs and preferences of an Internet-based clinical trial matching system.

Atkinson NL, Massett HA, Mylks C, Hanna B, Deering MJ, Hesse BW.

J Med Internet Res. 2007 May 15;9(2):e13.

18.

[Globalization of clinical trials].

Akaza H, Fukuoka M, Ohtsu A, Usami M, Ikeda T, Aiba K, Isonishi S, Ohashi Y, Saijo N, Sone S, Tsukagoshi S, Tsuruo T, Kato M, Mikami O, Dong RP, von Euler M, Blackledge G, Stribling D.

Gan To Kagaku Ryoho. 2003 Apr;30(4):555-65. Japanese.

PMID:
12722692
19.

Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.

[No authors listed]

Drugs R D. 2005;6(3):178-85. Review.

PMID:
15869322
20.

Physician-determined patient risk of toxic effects: impact on enrollment and decision making in phase I cancer trials.

Mick R, Lane N, Daugherty C, Ratain MJ.

J Natl Cancer Inst. 1994 Nov 16;86(22):1685-93.

PMID:
7966396

Supplemental Content

Support Center